Xiaowei Zang

Xiaowei Zang

Central US Merck & Co., Inc. - / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 5720035
person_outline Xiaowei Zang's MOST POPULAR ARTICLES
1-) Quantitative analysis of lab-to-lab variability in Caco-2 permeability assaysJB Lee, A Zgair, DA Taha, X Zang, L Kagan, TH Kim, MG Kim, H Yun, ...European Journal of Pharmaceutics and Biopharmaceutics 114, 38-42, 2017852017
2-) Prevention of paclitaxel-induced neuropathy by formulation approachX Zang, JB Lee, K Deshpande, OB Garbuzenko, T Minko, L KaganJournal of Controlled Release 303, 109-116, 2019342019
3-) Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokineticsX Zang, L KaganJournal of pharmacokinetics and pharmacodynamics 45, 577-592, 2018182018
4-) A randomized, double-blind, placebo-controlled, phase 1 trial of radiopaque islatravir-eluting subdermal implants for pre-exposure prophylaxis against HIV-1 infectionRP Matthews, X Zang, SE Barrett, A Koynov, A Goodey, T Heimbach, ...JAIDS Journal of Acquired Immune Deficiency Syndromes 92 (4), 310-316, 2023162023
5-) Next-generation islatravir implants projected to provide yearly HIV prophylaxisRP Matthews, X Zang, S Barrett, A Goodey, T Heimbach, V Weissler, ...Conference on Retroviruses and Opportunistic Infections (CROI), 6-10, 2021